UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 13, 2017

Commission File Number: 000-50768

 

 

ACADIA Pharmaceuticals Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   06-1376651

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

3611 Valley Centre Drive, Suite 300, San Diego, California 92130

(Address of principal executive offices)

858-558-2871

(Registrant’s Telephone number)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

  (e) On June 13, 2017, the stockholders of ACADIA Pharmaceuticals Inc. (“Registrant”) approved an amendment to Registrant’s 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 5,500,000 shares.

The foregoing description of Registrant’s 2010 Equity Incentive Plan, as amended, does not purport to be complete, and is qualified in its entirety by reference to Exhibit 99.1 to this Report, as well as the description of the 2010 Equity Incentive Plan, as amended, included in Registrant’s definitive proxy statement (the “proxy statement”) filed with the Securities and Exchange Commission on April 27, 2017.

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

  (a) Registrant held its 2017 Annual Meeting of Stockholders on June 13, 2017 (the “2017 Annual Meeting”).

 

  (b) The election of two nominees to serve as Class I directors on Registrant’s Board of Directors (the “Board”) until Registrant’s 2020 Annual Meeting of Stockholders was carried out at the 2017 Annual Meeting. The following two Class I directors were elected by the votes indicated:

 

     For      Withheld      Broker Non-
Votes
 

James Daly

     92,062,268        1,031,333        17,632,277  

Edmund Harrigan

     59,364,541        33,729,060        17,632,277  

In addition to the election of two Class I directors, the following matters were submitted to a vote of the stockholders at the 2017 Annual Meeting:

 

  (i) the approval of an amendment to Registrant’s 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 5,500,000 shares, which was approved by the following vote:

 

For   Against   Abstain   Broker Non-Votes
72,086,994   20,831,803   174,804   17,632,277

 

  (ii) the approval, on an advisory basis, of the compensation of Registrant’s named executive officers, as disclosed in the proxy statement, which was approved by the following vote:

 

For   Against   Abstain   Broker Non-Votes
81,129,579   11,738,911   225,111   17,632,277

 

  (iii) the indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of Registrant’s named executive officers, which received the following votes:

 

1 Year   2 Years   3 Years   Abstain
90,385,918   271,627   2,254,894   181,162

 

  (iv) the appointment of Ernst & Young LLP as Registrant’s independent registered public accounting firm for the fiscal year ending December 31, 2017 was ratified by the following vote:

 

For   Against   Abstain
109,080,043   1,112,223   533,612


Each of the foregoing voting results from the 2017 Annual Meeting is final.

 

  (d) Registrant had recommended that the advisory vote on executive compensation be done annually and, corresponding to the advisory vote received from stockholders at the 2017 Annual Meeting, will continue to hold annual advisory votes until Registrant’s next stockholder advisory vote on the frequency of advisory votes, which must be held at least once every six years.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

  

Description

99.1    2010 Equity Incentive Plan, as amended


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ACADIA Pharmaceuticals Inc.
Date: June 15, 2017     By:  

/s/ Glenn F. Baity

    Name: Glenn F. Baity
    Title:   EVP, General Counsel & Secretary


EXHIBIT INDEX

 

Exhibit No.

  

Description

99.1    2010 Equity Incentive Plan, as amended
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Acadia Pharmaceuticals Charts.